Pancreatic Cancer Research

ResearcherUNSW SydneyActive in the last 2 years

Joshua A. McCarroll

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8807-3623; OpenAlex author ID A5103231153. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  2. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  3. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  4. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  5. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. First author DOI 10.1158/0008-5472.can-20-2496↗
  6. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Co-author DOI 10.3390/cancers13102427↗
  7. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Co-author DOI 10.1016/j.biomaterials.2019.119742↗
  8. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Co-author DOI 10.18632/oncotarget.13985↗
  9. Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. First author DOI 10.1016/j.neo.2016.10.011↗
  10. βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2946↗
  11. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.3389/fphys.2014.00002↗
  12. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Co-author DOI 10.3389/fphys.2014.00141↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Goldstein · 12 shared papers, 2014–2026 · strength 1.31
  2. Phoebe A. Phillips · 12 shared papers, 2014–2026 · strength 1.31
  3. George Sharbeen · 11 shared papers, 2014–2026 · strength 1.26
  4. John Kokkinos · 7 shared papers, 2020–2026 · strength 1.05
  5. Amber L. Johns · 8 shared papers, 2015–2026 · strength 0.96
  6. Koroush Shahsavar Haghighi · 6 shared papers, 2021–2026 · strength 0.93
  7. Mert Erkan · 6 shared papers, 2015–2026 · strength 0.83
  8. Anthony James Gill · 5 shared papers, 2021–2026 · strength 0.79
  9. Val Gebski · 4 shared papers, 2021–2026 · strength 0.59
  10. Jennifer P. Morton · 4 shared papers, 2021–2026 · strength 0.59
  11. Marina Pajic · 4 shared papers, 2021–2026 · strength 0.58
  12. Australian Pancreatic Cancer Genome Initiative · 3 shared papers, 2020–2026 · strength 0.50
  13. Minoti Vivek Apte · 2 shared papers, 2021–2026 · strength 0.29
  14. Paul Timpson · 2 shared papers, 2021–2026 · strength 0.29
  15. Kendelle Joan Murphy · 1 shared paper, 2026 · strength 0.21
  16. James Ephraums · 1 shared paper, 2025 · strength 0.19
  17. Andrew Victor Biankin · 3 shared papers, 2015–2017 · strength 0.17
  18. Jie Liu · 2 shared papers, 2015–2021 · strength 0.13
  19. Angela S. Y. Chou · 1 shared paper, 2021 · strength 0.08
  20. Thomas R. Cox · 1 shared paper, 2021 · strength 0.08
  21. Nigel A. Turner · 1 shared paper, 2021 · strength 0.08
  22. Jessica L. Chitty · 1 shared paper, 2021 · strength 0.08
  23. Brooke Pereira · 1 shared paper, 2021 · strength 0.08
  24. Sigrid K. Fey · 1 shared paper, 2021 · strength 0.08
  25. Owen James Sansom · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.